- Trials with a EudraCT protocol (1,347)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,347 result(s) found for: Self diagnosis.
Displaying page 1 of 68.
EudraCT Number: 2022-003670-22 | Sponsor Protocol Number: IIBSP-OXI-2022-124 | Start Date*: 2023-07-31 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Controlled and randomized clinical trial to evaluate the efficacy of the combination of oxytocin plus self-compassion training in patients with Borderline Personality Disorder | ||
Medical condition: Borderline personality disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003870-21 | Sponsor Protocol Number: MG0020 | Start Date*: 2023-07-25 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011409-17 | Sponsor Protocol Number: LAST-RD - FARM77Z3BL | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA | |||||||||||||
Full Title: Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial. | |||||||||||||
Medical condition: Treatment-resistant depression and suicide risk. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003331-36 | Sponsor Protocol Number: FER-Loxapine-2015-01 | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:FERRER INTERNACIONAL SA | |||||||||||||
Full Title: A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting | |||||||||||||
Medical condition: Mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004054-28 | Sponsor Protocol Number: Panorexia | Start Date*: 2020-06-23 | ||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||
Full Title: Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study | ||||||||||||||||||
Medical condition: Anorexia Nervosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004357-82 | Sponsor Protocol Number: OSU6162ME1 | Start Date*: 2012-02-21 |
Sponsor Name:A. Carlsson Research AB | ||
Full Title: A randomized controlled trial of OSU6162 in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | ||
Medical condition: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001411-12 | Sponsor Protocol Number: CBYM338B2203E1 | Start Date*: 2015-11-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis | |||||||||||||
Medical condition: Sporadic Inclusion Body Myositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) DK (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002662-12 | Sponsor Protocol Number: PSY102 | Start Date*: 2012-12-12 | |||||||||||
Sponsor Name:Psyadon Pharmaceuticals Inc. | |||||||||||||
Full Title: An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects with Lesch-Nyhan Disease (LND). | |||||||||||||
Medical condition: Self-injurious behavior in subjects with Lesch-Nyhan Disease (LND). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000983-41 | Sponsor Protocol Number: ID-076A301 | Start Date*: 2021-11-03 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death a... | |||||||||||||
Medical condition: Acute myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) SK (Trial now transitioned) DK (Trial now transitioned) EE (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) IE (Prematurely Ended) GR (Trial now transitioned) PT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003395-13 | Sponsor Protocol Number: KOA-21-02 | Start Date*: 2022-03-03 | |||||||||||
Sponsor Name:Bioventus LLC | |||||||||||||
Full Title: A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particu... | |||||||||||||
Medical condition: Osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000830-38 | Sponsor Protocol Number: C87080 | Start Date*: 2008-10-07 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthriti... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) AT (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004261-14 | Sponsor Protocol Number: 1703001 | Start Date*: 2019-02-12 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003959-11 | Sponsor Protocol Number: 1703001 | Start Date*: 2020-05-25 |
Sponsor Name:Vestre Viken Trust | ||
Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study | ||
Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006514-42 | Sponsor Protocol Number: A-99-52030-216 | Start Date*: 2008-01-23 | |||||||||||
Sponsor Name:Institut Produits Synthèse (IPSEN) AB | |||||||||||||
Full Title: A PHASE IV, OPEN-LABEL, RANDOMISED, CROSS-OVER STUDY TO ASSESS PATIENT PREFERENCE AND HEALTH ECONOMY IN PATIENTS WITH NEUROENDOCRINE TUMOURS, TREATED WITH LANREOTIDE AUTOGEL GIVEN AS SELF ADMINISTR... | |||||||||||||
Medical condition: Symptoms associated with carcinoid syndrome in patients with neuroendocrine tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005213-11 | Sponsor Protocol Number: NES103694 | Start Date*: 2005-03-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with a... | |||||||||||||
Medical condition: Acute decompensated heart failure (adHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) IE (Completed) SK (Completed) HU (Prematurely Ended) IS (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) DK (Completed) LV (Completed) EE (Completed) FI (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003986-25 | Sponsor Protocol Number: ADAMPA | Start Date*: 2017-05-05 | |||||||||||
Sponsor Name:Instituto de Investigación Sanitaria INCLIVA | |||||||||||||
Full Title: Impact of self-measurement of blood pressure and self-adjustment of antihypertensive medication in the control of hypertension and adherence to treatment. A pragmatic, randomized, controlled clinic... | |||||||||||||
Medical condition: Arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005365-61 | Sponsor Protocol Number: ACCOST | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Med. Fakultaet der Friedrich-Alexander Universitaet Erlangen-Nuernberg | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS | |||||||||||||
Medical condition: Erosive osteoarthritis of the hand (EHOA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000441-32 | Sponsor Protocol Number: REDOX2016 | Start Date*: 2016-10-27 |
Sponsor Name:Blekinge county council | ||
Full Title: REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX) A Multicenter, Phase III, Registry-Based, Randomized Controlled Trial (R-RCT) | ||
Medical condition: Chronic respiratory failure requiring LTOT (long-term oxygen treatment) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003239-13 | Sponsor Protocol Number: PIMAT | Start Date*: 2017-10-02 | |||||||||||
Sponsor Name:Imperial College London JRC Office | |||||||||||||
Full Title: Pharmacokinetics of Intramuscular Adrenaline in Food-Allergic Teenagers - does dose matter? The PIMAT study | |||||||||||||
Medical condition: Anaphylaxis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000324-17 | Sponsor Protocol Number: GA18/118305 | Start Date*: 2019-08-02 | ||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||
Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
